Novartis | NVS - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
AbbVie USD 3.89B 325M 2025-12
Amgen USD 1.94B 237M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Bausch Health Companies USD 801M 6M 2025-12
Biogen USD 545.2M 38.6M 2025-09
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Canopy Growth CAD 28.9M 636K 2025-12
Corcept Therapeutics USD 114.74M 7.77M 2025-12
Drreddys Laboratories INR 26.92B 3.74B 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Glaxosmithkline GBP 3.56B 650.29M 2025-12
J&J USD 6.75B 831M 2025-12
Merck USD 2.85B 215M 2025-12
Novartis USD 3.44B 128M 2025-12
Novartis USD 3.44B 132M 2025-12
Pacira USD 91.87M 70K 2025-12
Perrigo USD 255.9M 10.2M 2025-12
Pfizer USD 4.08B 894M 2025-12
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 29.67M 1.64M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.75B 455M 2025-12
Sanofi EUR 2.75B 455M 2025-12
Supernus Pharmaceuticals USD 122.39M 57.29M 2025-12
Zoetis USD 619M 40M 2025-12